相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology
Karin Feldmann et al.
GASTROENTEROLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
Claudia X. Dominguez et al.
CANCER DISCOVERY (2020)
Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives
Yuki Miyai et al.
CANCER SCIENCE (2020)
Cancer associated fibroblast FAK regulates malignant cell metabolism
Fevzi Demircioglu et al.
NATURE COMMUNICATIONS (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities
Won Jin Ho et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
The role of fibroblast activation protein in health and malignancy
Allison A. Fitzgerald et al.
CANCER AND METASTASIS REVIEWS (2020)
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Hemant M. Kocher et al.
NATURE COMMUNICATIONS (2020)
Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer
Yoshiaki Sunami et al.
CANCERS (2020)
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial
Jobst Christian von Einem et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Yu Shi et al.
NATURE (2019)
A review of canakinumab and its therapeutic potential for non-small cell lung cancer
Kara M. Schenk et al.
ANTI-CANCER DRUGS (2019)
Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
Huocong Huang et al.
EMBO MOLECULAR MEDICINE (2019)
Vitamin D and Gastrointestinal Cancers: A Narrative Review
Hemant Goyal et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma
Giulia Biffi et al.
CANCER DISCOVERY (2019)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells
Yoshiaki Sunami et al.
CANCERS (2018)
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
James W. Purcell et al.
CANCER RESEARCH (2018)
CD10+ GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness
Shicheng Su et al.
CELL (2018)
A positive feedback loop bi-stably activates fibroblasts
So-Young Yeo et al.
NATURE COMMUNICATIONS (2018)
Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem
Xuexiang Han et al.
NATURE COMMUNICATIONS (2018)
412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)
I Melero et al.
ANNALS OF ONCOLOGY (2018)
Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
Viera Dobrotkova et al.
BMC CANCER (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
Yaqing Zhang et al.
GUT (2017)
Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer
Gemma Ferrer-Mayorga et al.
GUT (2017)
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Yufang Shi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Ohlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Targeting hepatic macrophages to treat liver diseases
Frank Tacke
JOURNAL OF HEPATOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy
Richard L. Sleightholm et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1-a phase I, first in human, first in class trial
Jobst C. von Einem et al.
ONCOTARGET (2017)
Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma
Albert Lo et al.
JCI INSIGHT (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF
Stephanie L. Merrigan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling
Xuguang Yang et al.
CANCER RESEARCH (2016)
Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization
Shigetsugu Takano et al.
GENES & DEVELOPMENT (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial
Hanno Niess et al.
BMC CANCER (2015)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Albert Lo et al.
CANCER RESEARCH (2015)
Chaperone Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene Network
J. Zhu et al.
CANCER RESEARCH (2015)
Interleukin-6 as a Therapeutic Target
Jean-Francois Rossi et al.
CLINICAL CANCER RESEARCH (2015)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma
Timothy J. Underwood et al.
JOURNAL OF PATHOLOGY (2015)
Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts
Keun-Woo Lee et al.
CANCER RESEARCH (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C. Oezdemir et al.
CANCER CELL (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Mara H. Sherman et al.
CELL (2014)
Evolutionary aspects of cancer resistance
George Klein
SEMINARS IN CANCER BIOLOGY (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma
Abasi Ene-Obong et al.
GASTROENTEROLOGY (2013)
The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis
Maximilian Reichert et al.
GENES & DEVELOPMENT (2013)
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia
Edward W. Roberts et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine
Brian Hutzen et al.
BMC CANCER (2012)
Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1
Oscar H. Ocana et al.
CANCER CELL (2012)
Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer
Sonal Gupta et al.
CLINICAL CANCER RESEARCH (2012)
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
Meredith A. Collins et al.
PLOS ONE (2012)
Retinoic Acid-Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt-β-Catenin Signaling to Slow Tumor Progression
Fieke E. M. Froeling et al.
GASTROENTEROLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system
Wei-Dong Yu et al.
CELL CYCLE (2010)
α-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma
Hayato Fujita et al.
PANCREAS (2010)
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α
Matthew Kraman et al.
SCIENCE (2010)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tocilizumab: The first interleukin-6-receptor inhibitor
Anthony Sebba
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts
Elinborg Ostermann et al.
CLINICAL CANCER RESEARCH (2008)
Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice
Lucia Kucerova et al.
JOURNAL OF GENE MEDICINE (2008)
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
Steven J. Cohen et al.
PANCREAS (2008)
Talabostat
Charles Casey Cunningham
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy
Lucia Kucerova et al.
CANCER RESEARCH (2007)
Vitamin D intake and the risk for pancreatic cancer in two cohort studies
Halcyon G. Skinner et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2
NP Gerard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Stromal antigen targeting by a humanised monoclonal antibody:: An early phase II trial of sibrotuzamab in patients with metastatic colorectal cancer
RD Hofheinz et al.
ONKOLOGIE (2003)
分享论文
